Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904098 · ClinicalTrials.gov registry record · Phase 4
Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT00904098: Completed Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00904098 is a Phase 4 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 192 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904098, a Phase 4 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
Females 18 years of age or older with at least one year history of menstrual migraine (MM) headaches participated in a Phase 4 clinical trial to evaluate the efficacy of frovatriptan when used at the early stage (International Headache Society \[IHS\] Grade 1) of MM compared with patients' current treatment.
Interventions
- DRUG Usual Care
- DRUG Frovatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904098
The ClinicalTrials.gov registry entry for NCT00904098 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT00904098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904098 about?
NCT00904098 is a clinical study titled "Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine". Females 18 years of age or older with at least one year history of menstrual migraine (MM) headaches participated in a Phase 4 clinical trial to evaluate the efficacy of frovatriptan when used at the early stage (International Headache Society \[IHS\] Grade 1) of MM compared with patients' current t...
What is the current status of trial NCT00904098?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 192 participants. The study started on 2005-09. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00904098?
The interventions under investigation include: Usual Care (DRUG), Frovatriptan (DRUG).
Who is sponsoring clinical trial NCT00904098?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.